[go: up one dir, main page]

AU2002314887A1 - Gads as modifiers of the p53 pathway and methods of use - Google Patents

Gads as modifiers of the p53 pathway and methods of use

Info

Publication number
AU2002314887A1
AU2002314887A1 AU2002314887A AU2002314887A AU2002314887A1 AU 2002314887 A1 AU2002314887 A1 AU 2002314887A1 AU 2002314887 A AU2002314887 A AU 2002314887A AU 2002314887 A AU2002314887 A AU 2002314887A AU 2002314887 A1 AU2002314887 A1 AU 2002314887A1
Authority
AU
Australia
Prior art keywords
gads
modifiers
pathway
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002314887A
Inventor
Marcia Belvin
Helen Francis-Lang
Lori Friedman
Roel P. Funke
Danxi Li
Gregory D. Plowman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AU2002314887A1 publication Critical patent/AU2002314887A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G01N33/57515—
    • G01N33/5752—
    • G01N33/57535—
    • G01N33/57545—
    • G01N33/5758—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4739—Cyclin; Prad 1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2002314887A 2001-06-05 2002-06-03 Gads as modifiers of the p53 pathway and methods of use Abandoned AU2002314887A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US29607601P 2001-06-05 2001-06-05
US60/296,076 2001-06-05
US32860501P 2001-10-10 2001-10-10
US60/328,605 2001-10-10
US35725302P 2002-02-15 2002-02-15
US60/357,253 2002-02-15
US36119602P 2002-03-01 2002-03-01
US60/361,196 2002-03-01
PCT/US2002/017465 WO2002098891A2 (en) 2001-06-05 2002-06-03 GADs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE

Publications (1)

Publication Number Publication Date
AU2002314887A1 true AU2002314887A1 (en) 2002-12-16

Family

ID=27501675

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002314887A Abandoned AU2002314887A1 (en) 2001-06-05 2002-06-03 Gads as modifiers of the p53 pathway and methods of use

Country Status (5)

Country Link
EP (2) EP1402051A4 (en)
JP (2) JP2005514906A (en)
AU (1) AU2002314887A1 (en)
CA (2) CA2448112A1 (en)
WO (4) WO2002098889A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012233044B2 (en) * 2002-11-22 2015-09-03 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
DE10254601A1 (en) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
AU2003297318A1 (en) * 2002-12-20 2004-07-22 Millennium Pharmaceuticals, Inc. Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
DE10316701A1 (en) * 2003-04-09 2004-11-04 Hinzmann, Bernd, Dr. New nucleic acid, and derived proteins, useful for diagnosis of bronchial cancer and in screening for therapeutic and diagnostic agents
EP1657311A4 (en) * 2003-07-11 2006-10-11 Banyu Pharma Co Ltd METHOD OF EVALUATING COMPOUND EFFECTIVE IN THE TREATMENT OF OBESITY
US20070087984A1 (en) * 2003-09-04 2007-04-19 Xiuyuan Hu Method of identifying agents that inhibit the growth of cancer cells
WO2005083425A2 (en) * 2004-02-26 2005-09-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with mitogen-activated protein kinase kinase kinase 13 (map3k13)
CN102097458B (en) 2004-06-04 2013-10-30 伊利诺伊大学评议会 Methods and devices for fabricating and assembling printable semiconductor elements
CN104637954B (en) 2007-01-17 2018-02-16 伊利诺伊大学评议会 The method for manufacturing semiconductor-based optical system
KR101870690B1 (en) 2009-05-12 2018-06-25 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 Printed assemblies of ultrathin, microscale inorganic light emitting diodes for deformable and semitransparent displays
WO2012097163A1 (en) 2011-01-14 2012-07-19 The Board Of Trustees Of The University Of Illinois Optical component array having adjustable curvature
WO2012158709A1 (en) 2011-05-16 2012-11-22 The Board Of Trustees Of The University Of Illinois Thermally managed led arrays assembled by printing
WO2012167096A2 (en) 2011-06-03 2012-12-06 The Board Of Trustees Of The University Of Illinois Conformable actively multiplexed high-density surface electrode array for brain interfacing
KR101979354B1 (en) 2011-12-01 2019-08-29 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 Transient devices designed to undergo programmable transformations
CN114181944B (en) * 2020-09-14 2023-10-03 中国科学院动物研究所 Mutated genes and methods and uses for constructing minipig models of short-limbed dwarfism

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69233507T2 (en) * 1991-02-22 2009-09-10 The Walter And Eliza Hall Institute Of Medical Research, Parkville HBGAD AND HIGAD POLYPEPTIDES AND NUCLEIC ACIDS AND THEIR USE FOR THE DIAGNOSIS AND TREATMENT OF GAD AUTOANTIGEN-ASSOCIATED DISEASES
US5405941A (en) * 1993-04-15 1995-04-11 National Jewish Center For Immunology And Respiratory Medicine MEKK protein, capable of phosphorylating MEK
US5554523A (en) * 1994-03-01 1996-09-10 Children's Hospital Of Philadelphia Nucleic acid sequences encoding human leucine-zipper protein-kinase
WO1999041385A1 (en) * 1998-02-13 1999-08-19 Cadus Pharmaceutical Corporation Mekk1 proteins and fragments thereof for use in regulating apoptosis
AU3354499A (en) * 1998-03-16 1999-10-11 Cadus Pharmaceutical Corporation Human mekk proteins, corresponding nucleic acid molecules, and uses therefor
EP1161542A1 (en) * 1999-03-18 2001-12-12 University Of Bristol Polysaturated fatty acid (pufa) elongase from caenorhabditis elegans
EP1173566A2 (en) * 1999-04-23 2002-01-23 Incyte Genomics, Inc. Human membrane-associated proteins
CA2342831A1 (en) * 1999-07-22 2001-02-01 The University Of British Columbia A plant long chain fatty acid biosynthetic enzyme
JP2003520032A (en) * 1999-11-12 2003-07-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 24 human secretory proteins
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001270045A1 (en) * 2000-06-20 2002-01-02 Incyte Genomics, Inc. Secreted proteins
CA2418266A1 (en) * 2000-08-11 2002-02-21 Merck Patent Gesellschaft Mit Beschraenkter Haftung Novel mitogen activated kinase
EP1341920A2 (en) * 2000-11-29 2003-09-10 Xenon Genetics, Inc. Human elongase genes and uses thereof
JP2005504503A (en) * 2001-02-06 2005-02-17 インサイト・ゲノミックス・インコーポレイテッド Receptors and membrane-related proteins
AU2002247691A1 (en) * 2001-02-08 2002-08-19 Bayer Aktiengesellschaft Regulation of human elongase hselo1-like protein
WO2002062975A2 (en) * 2001-02-08 2002-08-15 Bayer Aktiengesellschaft Regulation of human elongase hselo1-like protein
WO2002096943A1 (en) * 2001-05-25 2002-12-05 Asahi Kasei Kabushiki Kaisha Stat6-activating genes
AU2003231531A1 (en) * 2002-04-24 2003-11-10 Incyte Corporation Kinases and phosphatases

Also Published As

Publication number Publication date
CA2448112A1 (en) 2002-12-12
WO2002098889A2 (en) 2002-12-12
EP1402262A2 (en) 2004-03-31
CA2449479A1 (en) 2002-12-12
JP2005514906A (en) 2005-05-26
EP1402051A4 (en) 2005-08-17
JP2004532638A (en) 2004-10-28
WO2002098891A3 (en) 2003-05-30
WO2002098891A2 (en) 2002-12-12
WO2002099068A3 (en) 2003-12-04
EP1402262A4 (en) 2005-05-11
EP1402051A2 (en) 2004-03-31
WO2002099068A2 (en) 2002-12-12
WO2002098468A1 (en) 2002-12-12
WO2002098889A3 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
AU2002310256A1 (en) Ppp2cs as modifiers of the p53 pathway and methods of use
AU2003213606A1 (en) MP53s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2002352903A1 (en) Mesoporous materials and methods
AU2002320058A1 (en) Magnetic-nanoparticle conjugates and methods of use
AU2002324598A1 (en) Trps as modifiers of the p53 pathway and methods of use
AU2002314466A1 (en) Withasol and methods of use
AU2002314887A1 (en) Gads as modifiers of the p53 pathway and methods of use
AU2002239933A1 (en) Antineoplastic polyalkoxyalkylsiloxanes and methods of use thereof
AU2002337916A1 (en) Modifier of the p53 pathway and methods of use
AU2003248879A1 (en) RABS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2003295881A1 (en) Lamps as modifiers of the p53 pathway and methods of use
AU2003303094A1 (en) MAT2As AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2005042707A9 (en) Taspasel 1 and methods of use
AU2002355432A1 (en) Kavalactone compositions and methods of use
AU2002332130A1 (en) Msrebps as modifiers of the srebp pathway and methods of use
AU2002357817A1 (en) Klcs as modifiers of the p53 pathway and methods of use
AU2002345486A1 (en) Slc13as as modifiers of the p53 pathway and methods of use
AU2002312283A1 (en) Srpks as modifiers of the p53 pathway and methods of use
AU2002303951A1 (en) Glras as modifiers of the p53 pathway and methods of use
AU2002303947A1 (en) Pecis as modifiers of the p53 pathway and methods of use
AU2002314874A1 (en) Modifiers of the p53 pathway and methods of use
AU2002326718A1 (en) Tramdorins and methods of using tramdorins
AU2002361654A1 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
AU2003248876A1 (en) MP53S AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2003278811A1 (en) LDLRs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase